Quantification of stromal reaction in breast carcinoma and its correlation with tumor grade and free progression survival

Abstract Background: Breast carcinoma is the most common malignancy in female worldwide, leading cause of death in women.immunohistochemistry plays a very important role in the prognostication and treatment determination of breast carcinoma patients. Objective: To analyze the immunohistochemical markers in invasive carcinoma of breast and to correlate the expression of hormonal receptors with age of the patient, tumor size, histological grade and lymph node metastasis.Materials and method: The study was conducted on 88 infiltrating ductal breast carcinoma sample in a tertiary care hospital of Southern Assam for a period of two year (January2018- December 2019). Data including age, tumor size, and histologic grade and lymph node status retrieved from pathology department. Chi- square was used to determine the statistical significance between ER/PR status HER2/neu status along with their correlation with various clinicopathological parametres with respect to infiltrating ductal breast carcinoma.Result: The mean age of the patients was 56.6 years. We observed correlation between ER and PR expression with age, tumor size, tumor grade. There was correlation between HER2/neu expression and age only. None of the markers showed correlation with lymph node involvement (P>0.05).Conclusion: Our findings showed the importance of biomarkers (ER, PR, HER2/neu) expression as prognostic factors for therapeutic decision.

Download Full-text

Concordance of histology type between synchronous and metachronous contralateral breast carcinoma: Is there susceptibility for breast cancer of particular histology?

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.15_suppl.e21030 ◽

2012 ◽

Vol 30 (15_suppl) ◽

pp. e21030-e21030

Author(s):

Zorica Tomasevic ◽

Dusica Gavrilovic ◽

Zoran Tomasevic ◽

Daniela Kolarevic

Keyword(s):

Breast Cancer ◽

Breast Carcinoma ◽

Statistical Difference ◽

Lobular Carcinoma ◽

Progesterone Receptors ◽

Distant Metastases ◽

Tumor Grade ◽

Contralateral Breast ◽

Molecular Characteristics ◽

Significant Difference

e21030 Background: Contra-lateral breast cancer (CBC) is considered to be the most frequent new malignancy after primary breast cancer (PBC) However, there are few reports whether the histology and other major molecular characteristics differs between PBC and CBC. The aim of this paper is toevaluate and compare PBC/CBC histology according to the time to CBC development. Also, age at CBC and major molecular characteristics (tumor grade, estrogen/progesterone receptors, HER2) have been analyzed. Methods: A cohort of 113 patients with CBC, without distant metastases, has been prospectively registered during 28 months. Patients are divided in 2 groups according to the time of CBC diagnose: 1. Synchronous, if the CBC (S-CBC) was diagnosed either simultaneously or within 6 months after PBC; 2. Metachronous (M-CBC) if CBC was diagnosed > 6 months after PBC. Results: Results are presented in Table 1. Median age was calculated at the time of CBC diagnose. Patient with S-CBC are median 7 years older than patients with M- CBC that is statistically significant difference (p-0.007) S-CBC is more likely to be of the same histological type (76%) than M-CBC (56%) (p 0.006) In the whole analyzed group, and each subgroup separately, lobular carcinoma is registered in higher percentage (41%) than expected (~20%) For all other analyzed BC characteristics, statistical difference was not confirmed, however ~ 25% of specimens were not available for testing. Conclusions: Although it is still unclear what could be the clinical significance of these findings, genetic susceptibility to particular histology type of BC might be reasonably speculated. [Table: see text]

Download Full-text

Foetal antigen 2 (FA2) in the stromal reaction induced by breast carcinoma

Apmis ◽

10.1111/j.1699-0463.1992.tb00837.x ◽

1992 ◽

Vol 100 (1-6) ◽

pp. 39-47 ◽

Cited By ~ 15

Author(s):

H. BOJE RASMUSSEN ◽

B. TEISNER ◽

J. A. ANDERSEN ◽

E. YDE-ANDERSEN ◽

K. SKJØDT ◽

...

Keyword(s):

Breast Carcinoma ◽

Stromal Reaction

Download Full-text

Evaluation and Reinforcement of the Correlation of S-Phase Fraction with Nodal Metastases, Tumor Grade and Tumor Size in Breast Carcinoma Patients in Pakistan

Pathology - Research and Practice ◽

10.1078/0344-0338-00123 ◽

2001 ◽

Vol 197 (8) ◽

pp. 531-536 ◽

Cited By ~ 1

Author(s):

Humayun Bakhtawar ◽

Naureen Munawar Ali ◽

Shaista Khan ◽

Syed Abdul Aziz ◽

Tariq Sliddiqui ◽

...

Keyword(s):

Breast Carcinoma ◽

Tumor Size ◽

Tumor Grade ◽

S Phase ◽

Phase Fraction ◽

Nodal Metastases

Download Full-text

Is Oncotype DX Testing Necessary For Patients With Node Negative, Low-Grade Invasive Ductal Breast Carcinoma?

American Journal of Clinical Pathology ◽

10.1093/ajcp/aqab191.050 ◽

2021 ◽

Vol 156 (Supplement_1) ◽

pp. S26-S26

Author(s):

M Ali ◽

D Mandich ◽

M Assaad ◽

R W Cartun

Keyword(s):

Breast Carcinoma ◽

Tumor Grade ◽

Oncotype Dx ◽

Small Subset ◽

Low Grade ◽

Invasive Ductal Breast Carcinoma ◽

Node Negative ◽

Prognostic Features ◽

Ductal Breast Carcinoma ◽

Er Positive

Abstract Introduction/Objective Oncotype DX (Genomic Health/Exact Sciences, Redwood City, CA) is a 21-gene expression test that is used to predict the risk of recurrence following hormonal therapy and adjuvant chemotherapy (CT) benefit for patients with early-stage, ER-positive and HER2-negative invasive breast carcinoma (IBC). Testing is performed on formalin-fixed, paraffin-embedded tumor tissue from patients that are either lymph node (LN) negative, have micro- metastases, or 1-3 positive LNs. For years pathologists have studied traditional prognostic features of IBC (tumor grade, size, and LN status), as well as biomarker testing results (ER, PR, HER2, and Ki-67), in an effort to identify surrogate equations that could help identify patients that would benefit from CT. The “TAILORx” clinical trial, performed to study CT benefit in patients with midrange recurrence scores (11-25), has shown that the majority of these patients do not derive benefit from CT. Post-TAILORx, we have observed that only a small subset of our node- negative patients who were tested showed a benefit for CT. Following the examination of Oncotype DX results from testing performed on our patients, we hypothesized that overall tumor grade (Nottingham) might predict which patients with invasive ductal breast carcinoma (IDBC) do not require Oncotype DX testing; therefore, eliminating the need for Oncotype DX testing. Methods/Case Report We reviewed the surgical pathology reports and Oncotype DX reports for 251 patients with node-negative disease who underwent surgery at our institution from September 2019 through June 2021. All excisional tumors sent for Oncotype DX testing were ER-positive (Allred score ≥6/8) and HER2-negative by IHC and/or FISH. Results (if a Case Study enter NA) Oncotype DX recurrence scores ranged from 0-65. A benefit for CT was seen in 10.4% (26/251) of the patients with node-negative IDBC. A benefit for CT was seen in 6.1% (7/114) of patients with an overall tumor grade of II and 44.2% (19/43) of patients with an overall grade of III. No patients (0/94) with IDBC and an overall tumor grade of I showed a benefit for CT. Conclusion In the post-TAILORx era, patients with ER-positive (Allred ≥6/8), HER2-negative IDBC, who are node- negative and show an overall tumor grade of I, apparently do not require Oncotype DX testing. Additional studies from other institutions are needed to confirm our observation.

Download Full-text

WE-D-304A-05: Analysis of Tumor Grade Breast Carcinoma Using Computer-Extracted Morphological and Kinetic Features in DCE-MRI

Medical Physics ◽

10.1118/1.3182541 ◽

2009 ◽

Vol 36 (6Part26) ◽

pp. 2778-2778

Author(s):

N Bhooshan ◽

M Giger ◽

S Jansen ◽

H Li ◽

L Lan ◽

...

Keyword(s):

Breast Carcinoma ◽

Tumor Grade ◽

Dce Mri ◽

Kinetic Features

Download Full-text

Clinical and histopathologic tumor characteristics in patients with invasive breast carcinoma receiving metformin.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.27_suppl.165 ◽

2012 ◽

Vol 30 (27_suppl) ◽

pp. 165-165

Author(s):

Nikola Besic ◽

Barbara Gazic ◽

Nika Satej

Keyword(s):

Breast Carcinoma ◽

Statistical Difference ◽

Lobular Carcinoma ◽

Tumor Grade ◽

Study Groups ◽

Tumor Stage ◽

Lower Proportion ◽

Metformin Group ◽

Her 2 ◽

Dm Type 2

165 Background: Although both diabetes mellitus (DM) and breast carcinoma (BC) are common diseases, the data about histopathology characteristics and extent of disease of these patients in the literature are scarce and conflicting. Metformin may exhibit inhibitory effects on cancer cells by inhibiting mTOR signaling pathway. Our hypothesis was that use of metformin has an impact on slower progression of breast carcinoma in comparison to other types of anti-diabetic drugs. The aim of our retrospective study was to examine if the patients with BC and DM receiving metformin have lower tumor stage in comparison to patients not receiving metformin. Methods: A chart review of 252 patients (mean age 66.6; range 38-93 years) with invasive BC and DM was performed. They were surgically treated at our institute from 2005-2011. Data on clinical and histopathology factors were collected. Statistical analysis of these factors (i.e., comparison of metformin group vs. no metformin group) was performed by contingence tables and non-parametric tests. Results: DM type 1 and DM type 2 was present in 14 and 238 cases, respectively. Altogether 126 patients were on metformin, while 126 were not receiving metformin. Larger proportion of patients on metformin in comparison to patients not receiving metformin was younger than 71 years of age (p<0.05). No statistical difference between the study groups (metformin vs. no metformin) were found in TNM stage (T1: 48% vs. 46%; T2: 36% vs. 28%; T3: 7% vs. 5%; T4: 9% vs. 21%, p=0.071; N0: 51% vs. 50%, N1 49% vs. 50%; M0: 97% vs. 97.5%, M1: 3% vs. 4%, p=0.74, respectively). However, patients on metformin had lower proportion of T3 or T4 tumors than patients who were not receiving metformin (16% vs. 26%; p<0.05). Patients on metformin had lower rate of lobular carcinoma than patients who were not receiving metformin (9.5% vs. 19%; p<0.05). Tumor size, tumor grade, mean number of metastatic lymph nodes, hormone receptor status or HER-2 status did not show any statistical difference between both study groups. Conclusions: Patients with BC and DM on metformin have lower proportion of T3 or T4 tumors and lower proportion of lobular carcinoma in comparison to patients not receiving metformin.

Download Full-text